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ABSTRACT 
THE COMPARISON OF CO-STIMULATORY SURFACE MOLECULE 
EXPRESSION ON HUMAN MONOCYTE-DERIVED DENDRITIC CELLS 
INFECTED WITH TWO STRAINS OF INFLUENZA VIRUS 
By 
 
Jessie M. Simmon 
 
The early immune response against influenza is not well understood. The goal of the 
present work was to investigate co-stimulatory surface molecule expression between two 
strains of influenza virus.  It has been demonstrated that foot-and-mouth-disease virus 
(FMDV) infection in mice causes a down-regulation of activation molecules in dendritic 
cells (DC) while inactivated FMDV induces expression of co-stimulatory surface 
molecules. Influenza virus and FMDV are cytopathic and both induce a T-cell 
independent response to clear infection. In this thesis, monocytes from whole blood were 
magnetically separated using a biotinylated antibody against the CD14 molecule. These 
monocytes were cultured with cytokines, and differentiated into DC, and were infected 
with two strains of influenza virus. Each sample was stained with a panel of antibodies 
specific for molecules involved in DC activation. The results indicated that a strain of 
influenza that currently infects the human population down-regulates activation 
molecules on human monocyte-derived DC. In contrast, DC infected with the avian-
adapted strain demonstrated an up-regulation of activation molecules. The human 
adapted strain behaves similarly to infectious foot-and-mouth disease virus, while the 
avian adapted strain behaves like inactivated FMDV in human monocyte-derived DC. 
The implications of these findings for the understanding of the early protective immune 
response against different strains of the influenza virus are discussed.  
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1 
 
INTRODUCTION 
 
 
 
Immune response against a pathogen in mammalian hosts 
 
Over the course of evolution, the immune systems of mammals species have been 
constantly challenged by microbial pathogens such as fungi, bacteria, and viruses, and the 
host species have developed immune responses against them. Most viruses infect their 
hosts through mucosa in the respiratory, gastrointestinal or urogenital tracts, and replicate 
in the tissues of their hosts and this in turn produces an immune response to oppose 
infection. 
 
The immune system of mammals comprises two main sub-systems: innate and adaptive. 
The innate immune system comprises several cell types and molecules that non-
specifically recognize the presence of a virus in the host. The result of this non-specific 
recognition is the activation of cells involved in the first response against viral infections. 
These cells secrete a number of molecules that mediate communication between cells. 
These mechanisms are collectively named non-specific recognition because even though 
the presence of the infection is sensed, the specific virus is not fully recognized. As a first 
responder, the innate immune system blocks the replication of viruses and contains the 
spread of infections until a stronger and more specific response can be produced by the 
adaptive immune system. The adaptive immune response is not universal, and the 
strategy of infection of the virus will determine the appropriate adaptive immune 
response against it.  
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In the last ten years, it has become clear that the innate immune response is also 
responsible for determining the appropriate adaptive immune response against viral 
infection. Several cells are involved in the adaptive response host. The influenza virus is 
a common pathogen that infects mammals and birds. The viral receptors are recognized 
by the immune system of the host as antigens. Initial recognition of a pathogen by a 
group of specific cells of the immune system called “antigen presenting cells” initiates 
the adaptive immune response. The cells that present antigens include dendritic cells, B 
cells, and macrophages. Dendritic cells are the most efficient antigen presenting cells that 
activate other immune system cells by providing specific and non-specific stimuli. T 
cells, in particular, become activated when dendritic cells express surface major 
histocompatibility complexes (MHC) on their cell membrane (Figure 1) and other co-
stimulatory molecules are expressed as well.  
 
Figure 1. Illustration of a MHC molecule expressed on the outside of a dendritic cell 
membrane. The antigen exposed by the molecule is of the influenza virus. MHC 
molecules are crucial for the clearance of pathogens infecting a host. 
 
 
When an immature dendritic cell interacts with a pathogen such as an influenza virus 
particle, they undergo a maturation process that includes the expression of surface 
molecules and the release of pro-inflammatory cellular messengers known as cytokines. 
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Once this maturation process is complete, the dendritic cell then acts to activate certain 
cells of the immune system.  
Figure 2. T-cell dependent response. Professional antigen presenting cells (such as 
dendritic cells) express viral antigens (such as influenza virus) to T cells. This 
subsequently stimulates B cells to produce antibodies specific against the influenza virus 
antigen. Antibody production further allows for clearance of the virus or helps to 
moderate the disease caused by the infection. 
 
 
Cells that produce antibodies are called B lymphocytes (B cells) and they can be divided 
in three different cell populations. The most numerous are the follicular B cells or B2 
cells that circulate permanently in the body, contacting pathogens in the lymph nodes. 
The second group are the B1 cells, that are located predominantly in the body cavities, 
and these cells produce antibodies against conserved molecules of pathogens, especially 
sugars present on the cell walls of bacteria. B cells can be activated to produce antibodies 
in two ways. The first way is through a T-cell dependent response:  peptides from the 
pathogen are expressed in association with MHC molecules on the cell membrane of 
antigen presenting cells. This name refers to the concept that in order to induce the most 
efficient and effective antibody response from B cells, T cells must be involved. T cells 
secrete cytokines and express activating molecules on their cell membrane to activate the 
B cell. This activation includes proliferation of the B cells into plasma cells, isotype 
Influenza virus 
Dendritic Cell 
   
 
          T cell      B cell    α- Influenza virus  
       antibodies 
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switching, and memory cell generation. A model for the typical adaptive T cell dependent 
immune response against a pathogen is shown in Figure 2.  
 
Some bacteria and viruses induce a response in which there is no T cell involvement. 
These responses are called T-cell independent responses (Figure 3). Here, T cells are 
bypassed, and the antigen presenting cell directly activates B cells to produce antibodies.  
These immune responses are faster than the T-cell dependent responses. 
 
Figure 3. T-cell independent response. Dendritic cells are loaded with influenza virus. As 
a result, the dendritic cell activates the B cell, and by-passes the T cell. 
 
 
Early immune response against cytopathic viruses 
The pathology associated with cytopathic viruses that induce acute infections is increased 
by the interference of the normal physiology of the host cell. The virus rapidly replicates, 
causing extended tissue injury in only a few days, so the induction of a protective 
immune response must be rapid. After infection of naïve individuals, both neutralizing 
antibodies and cellular immunity responses may be necessary to clear the virus. With 
some viruses, neutralizing antibodies seem to be the main branch of the immune response 
involved in viral clearance. Indeed, a strong protective neutralizing antibody-mediated 
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response against several cytopathic viruses is induced early after infection without the 
involvement of CD4 T helper cells, by a T cell independent response.  
 
For example, in 1986, Charan and Zinkernagel demonstrated that three days after 
infection with vesicular stomatitis virus, neutralizing antibodies with high affinity are 
detected in blood,  and the vesicular stomatits virus is cleared (1). In addition, immune 
response against polyoma virus, rotavirus, and influenza virus are also T cell independent 
(2-4). It has been demonstrated that the immune response against infectious foot-and-
mouth disease virus is T cell independent while the immune response against inactivated 
FMDV is T cell dependent (5,6). However, CD4 T helper cells are necessary to establish 
long-lasting immunological memory after infection (7).  
 
The lack of CD4+ T cell involvement at the beginning of infection could be thought as an 
escape mechanism of these viruses since T cells are one of the two main populations of 
the adaptive immune system. It is hypothesized that this a physiological mechanism in 
mammals that evolved to induce a rapid induction of neutralizing antibodies to decrease 
the viral load at the peak of the infection while T cell dependent response matures and 
induces a long-lasting protective response.  
 
Immune response against influenza virus 
Influenza virus is a cytopathic virus belonging to the family Orthomyxoviridae. It has a 
lipid membrane (envelope) and a segmented negative single-stranded RNA genome. The 
current inactivated (non-infectious) vaccine against influenza induces immunity around 
15 days after vaccination and the immunity conferred is short-lasting. The goal for this 
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vaccine is to induce neutralizing antibodies against the prevalent strains of influenza in 
the season, but the antibodies only last for a few months. In contrast, infection with 
influenza induces neutralizing antibodies more rapidly and the immunity is long-lasting. 
Thus, although the vaccine and the infection produce antibodies against the virus, the 
kinetics and the outcomes are significantly different, suggesting different pathways. The 
mechanisms involved in these different pathways of the immune response are only 
partially known.   
 
The basic parameters of the immune response against infection with influenza have been 
very well characterized in humans and mice. Although infection of mice does not 
produce the same disease in humans, the availability of reagents and of genetically 
modified mice provides a bountiful supply of information regarding the pathogenicity 
and immune response induced. In 1998, Epstein et al. demonstrated that CD4+ and CD8+ 
cells generated by intra-nasal infection of C57BLK6 mice with influenza A/PR/8/34 
(H1N1) were sufficient to protect from re-infection (8). Roman et al. confirmed this in 
1986 by demonstrating protection of irradiated mice adoptively transferred with CD4+ 
and CD8+ cells followed by a challenge with influenza (9,10).  
 
However, the absence of B cells is not protective, even in the presence of CD8+ specific 
T cells, indicating that antibodies are necessary for protection against this virus (11). The 
early immune response against influenza is T-cell independent. This was shown in T 
helper cell deficient mice and in CD40 knock-out mice (11,12). Moreover, isotype 
switching from IgM to IgG was also found in these mice, and these antibodies protected 
the mice from re-infection up to 60 days post-infection (13). These results demonstrated 
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that there is a T cell independent pathway at the beginning of infection but T helper cells 
are necessary for the establishment of immunological memory. These results are similar 
to the ones obtained by Ostrowski et. al. in 2005 using a mouse model for foot-and-
mouth-disease virus (6). 
 
Bender et. al. demonstrated in 1998 that macrophages, but not dendritic cells undergo 
apoptosis following infection with influenza. Using monocytes from blood and cytokine-
derived dendritic cells, it was demonstrated that only very low levels of virus were 
actually produced from infected dendritic cells. Bender et. al. concluded that influenza 
virus infection in dendritic cells is non-toxic and unproductive (14).  
 
Oh et. al. demonstrated in 2000 that there was a decrease in allogenic T cell proliferation 
with influenza infected murine dendritic cells at a multiplicity of infection of 12.5 or 
greater. However, at a lower multiplicity of infection, there is an increase in T cell 
response, whereby dendritic cells were loaded with UV inactivated virus. Although 
relevant to this study, Oh et al. did not investigate the role of interference particles from 
influenza infection, and so it is difficult to comment on the significance of the differences 
seen with a lower multiplicity of infection. However, influenza infected dendritic cells 
down-regulate T cell responses due to the decrease in proliferation that accompanies 
higher multiplicity of infection. These researchers did not investigate co-stimulatory 
molecules expressed on influenza infected dendritic cells, but their findings suggest that 
there could be a decrease in the expression of co-stimulatory molecules as has been found 
to be the case with dendritic cells infected with foot-and-mouth disease virus (15).  
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Dendritic cells loaded with UV inactivated foot-and-mouth disease virus up-regulate 
activation markers and induce a typical T-cell dependent response, while dendritic cells 
infected with active foot-and-mouth disease virus down-regulate activation molecules 
and induce a T cell independent response (5,6). These results suggest that two different 
pathways are utilized to induce neutralizing antibodies- one for infectious virus and the 
other for inactivated foot-and-mouth disease virus. 
 
Oh et al. also demonstrated that A/PR/8/34, an H1N1 influenza virus, abortively infects 
human monocyte-derived dendritic cells which fail to induce a strong Th1 immune 
response. Up-regulation of co-stimulatory molecules, cytokine secretion, and expression 
of several genes involved in the IFN-α/β response and in dendritic cell activation were 
investigated in this work (15).  
 
In 2006, Fernandez-Sesma et al. found that influenza-infected dendritic cells exhibit a 
down-regulation of MHC Class II and CD86 molecules. These researchers concluded that 
this is a mechanism of viral evasion from the immune system (16). Based on the results 
with foot-and-mouth-disease virus, as well as those of other researchers working in other 
cytopathic viruses, it is hypothesized that the down-regulation reported by Fernandez-
Sesma et al. is indeed a mechanism of the immune system to decrease inflammation 
induced by activation of T cells by dendritic cells at the peak of the infection, rather than 
a mechanism of escape for the virus (16).  
 
If this hypothesis is correct then it is predicted that a current human strain of influenza 
virus such as A/Memphis/102/72 (H3N2) will decrease activation molecules expressed 
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by infected dendritic cells while an avian adapted strain (such as A/WSN/33 (H1N1)) 
will increase activation molecules on dendritic cells. 
 
Project Significance 
 
 
The influenza strain responsible for the 1918 pandemic killed 50 million people 
worldwide over the course of two years. To date, this is the worst-ever influenza 
pandemic. It is of particular interest that many affected by this strain were mostly middle 
aged individuals, ranging from 20 to 40 years of age. Many researchers consider that 
another pandemic is inevitable, and could happen at any time. 
 
In the United States, seasonal influenza causes more than 36,000 deaths and more than 
200,000 hospitalizations every year. This type of influenza commonly affects 
immunocompromised individuals, so it is important to understand the early protective 
immune response against influenza in humans. In addition to the risk of another 
pandemic, and the constant burden of seasonal influenza, strains of the virus to which the 
human population has no immunity constitute a high risk for pandemic activity. As seen 
with the Spanish flu of 1918, another pandemic could be capable of killing millions of 
people due to high pathogencity, and the impact on the global economy could be 
catastrophic.  
 
This research provides an insight into the early protective human immune response 
against influenza virus, and will help to understand the early rapid protective response 
achieved after infection with influenza. Ultimately, this knowledge could be beneficial 
for the engineering of effective vaccines that may provide longer immunity to influenza.  
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This research could lead to an explanation as to why differences are noted between the 
pathogenicity of different strains of influenza in humans.  
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CHAPTER 1: OPTIMIZATION OF PROTOCOLS 
 
1.1 Methods/Materials 
 
1.1.1 Propagation of influenza virus in embryonated chicken eggs 
Stock influenza virus was used to carry out several key experiments in this thesis. The  
following protocol was used to propagate influenza virus used in subsequent experiments.  
Embrocated chicken eggs were kept at 37°C and 5% humidity in an incubator. Each day  
at 10:00 am, prior to infection, the eggs were turned to ensure viability.  
 
On the tenth day of incubation, the eggs were candled to mark the air sacs by holding it  
up to a candlebox. The clear area seen through the shells was marked with a pencil  
(Figure 4). Working in sterile conditions each egg was sprayed with 70% ethanol and  
punched along the line of the air sac using an 18 gauge needle, and 0.1 mL of a 5000 U- 
µg penicillin-streptomycin (Gibco) solution was injected (Figure 4). The eggs were once  
again sprayed with 70% ethanol and injected with 0.2 mL dilution of influenza virus.   
Influenza viruses A/Memphis/102/72 (H3N2) and A/WSN/33 (H1N1) were provided by  
Dr. Rubin Donis of the Centers for Disease Control (Atlanta, GA) and were diluted in  
1X PBS solution adjusted to pH 7.4. The stock influenza virus was stored at -80°C.  
After viral infection, the puncture holes on the eggs were taped, and eggs were incubated  
for 48 hr at 37°C and 5% humidity. After incubation eggs were put at either -20°C for 30 
 minutes or 4°C overnight to clot the blood. The eggs were opened in sterile conditions,  
and allantoic fluid was collected from each egg.  All fluid was centrifuged at 4°C at  
12,000 RPM for 15 minutes. The supernatants were collected in sterile conditions and  
aliquoted in 1 mL amounts. Once aliquoted, all samples were stored at -80°C. 
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Figure 4. Top Left: Diluting influenza virus using 1X PBS pH 7.4 in sterility. Top Right: 
Boring the injection site in the window area of egg. Middle Left: Injecting egg with 5000 
U-µg penicillin-streptomycin solution. Middle Right: Injecting each egg with 0.2 mL 
virus dilution diluted in 1X PBS. Bottom Left: Wiping each egg with 70% ethanol, then 
taping and labeling. Bottom Right: Incubating eggs after infection 48 hours at 37°C and 
5% humidity. After 48 hours, all eggs were held at -20°C for 30 minutes prior to 
harvesting the allantoic fluid.  
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1.1.2 Blood collection and storage 
The experiments in this thesis required the use of infectious influenza virus. To  
effectively design these experiments, influenza virus propagated in embryonated chicken  
eggs needed to be quantified by hemagglutination titration that allowed the virus to be  
quantified in terms of hemagglutination units (HAU). In this method, chicken red blood  
cells (CRBC) are used to show a HAU. It is necessary to have 1 x 106 virus particles to  
make one HAU. 
  
To preserve collected chicken blood it is necessary to dilute it in Alsevers solution that  
was made in sterile conditions prior to blood collection. Five mL whole blood was  
collected from 6 month old female chickens using 5 mL sterile Alsever’s solution  
and 23-gauge needles. Each drawing site was thoroughly wiped with alcohol. After  
collection, the sites were again cleaned with alcohol and cotton was placed between the  
wing and the body of the chicken for 5 minutes to control bleeding. The blood was then  
transferred to sterile conical tubes and stored at 4°C for up to 30 days. 
 
1.1.3 Hemagglutination unit titration 
To perform the titration, 2.5 mL of chicken blood stored in Alsevers solution was rinsed  
three times with sterile 10 mL 1XPBS pH 7 at 2000 RPM for 5 minutes. After the last  
rinse the supernatant was removed and 0.4 mL of pooled chicken red blood cells was  
collected and diluted in 39.6 mL sterile 1X PBS pH 7. Fifty microliters of 0.5%  bovine  
serum albumin (BSA) in 1X PBS pH 7 was added to each well in a 96 well plate,  
excluding the first column.  
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One hundred microliters of undiluted propagated virus (A/WSN/33 and 
A/Memphis/102/72) was added to appropriate wells in the first column. A fifty microliter 
sample from this column was then collected and pipetted into the next column using a 
multi-channel pipettor.  The well contents were then mixed 10 times by pipetting up and 
down slowly. Fifty microliters of column 2 were then pipette into column 3, and mixed. 
This was repeated for all columns excluding the last. Fifty microliters of CRBC solution 
was then added to each well starting with the last column as demonstrated in Figure 5. 
The contents of the last column contained only 0.5% BSA solution and CRBC solution.  
The plate was then incubated at room temperature for 30 minutes in sterile conditions.  
Wells were then noted for agglutination. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1096 1:2192 Control 
B             
C             
D             
E             
F             
G             
H             
Figure 5.  Diagram illustrating organization of influenza viral titration determined by 
hemagglutin units.  The diagram above represents a 96 well plate.  Each well of column 1 
received 50 µl of influenza virus and 50 µl of 1% CRBC solution, each well of column 2 
received 50 µl of influenza diluted 1:2 with 0.5% BSA solution, and 50 µl of 1% CRBC 
solution, etc, up to column 11.  Column 12 did not receive influenza virus, and served as 
the internal control. 
 
 
1.1.4 Determination of the egg infectious dose of propagated influenza virus 
The HAU titer of a virus indicates the number of virus particles (infectious and non- 
infectious) in a volume of influenza virus suspension. For the purposes of this thesis, it  
was necessary to use an egg infection dose (EID) method in order to determine infectivity  
of the propagated viruses. Embryonated chicken eggs were kept at 37°C and 5%  
humidity. Every day prior to infection eggs were turned at approximately 10 a.m. 
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On the tenth day of incubation, the eggs were candled to mark the air sac. Dilutions of  
A/WSN/33 (HAU 1:256) were made using sterile 1X PBS. The dilutions were then  
inserted in 1 mL syringes. Dilutions of A/Memphis/102/72 (HAU 1:512) were made in  
1X PBS. The eggs were sprayed with 70% ethanol and punched along the line of the air  
sac using an 18-gauge needle. One hundred microliters of a 1000 U/ml penicillin- 
streptomycin (Gibco) solution was injected into each egg.  The eggs were once again  
sprayed with 70% ethanol and were injected with 0.1 mL of virus dilution.  
 
After viral infection, puncture holes on the eggs were taped. Eggs were incubated for 48  
hr at 37°C and 5% humidity. After incubation, eggs were held at either -20°C for 30  
minutes or at 4°C overnight to clot the blood. The eggs were opened in sterile conditions,  
and allantoic fluid was collected from each egg.  All fluid was centrifuged at 4°C at  
12,000 RPM for 15 minutes.  Two and a half mL of chicken blood was stored in Alsevers  
solution was rinsed three times with sterile 10 mL 1X PBS pH 7 at 2000 RPM for 5  
minutes. After the last rinse the supernatant was removed and 0.4 mL of pooled CRBC  
was collected and diluted in 39.6 mL sterile 1X PBS pH 7. Two 96 well plates were used  
to determine of the EID of each virus strain. Figure 6 shows the design for the titration of  
A/WSN/33. Figure 7 shows the design for the titration of A/Memphis/102/72. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
 10-4 10-5 10-6 10-7 10-8 control       
A       X X X X X X 
B       X X X X X X 
C       X X X X X X 
D       X X X X X X 
E 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 1:8192 1:16384 
F             
G             
H             
Figure 6. The plate design for the determination of EID of propagated A/WSN/33. The 
first column from A1-C1 contains 50 microliters of a 1% CRBC solution and 50 
microliters of allantoic fluid from the set of eggs infected with a dilution of 10-4. Column 
A2-C2 contains 50 microliters of a 1% CRBC solution and 50 microliters of allantoic 
fluid from the set of eggs infected with a dilution of 10-5. Column A3-C3 contains 50 
microliters of a 1% CRBC solution and 50 microliters of allantoic fluid from the set of 
eggs infected with a dilution of 10-6. Column A4-C4 contains 50 microliters of a 1% 
CRBC solution and 50 microliters of allantoic fluid from the set of eggs infected with a 
dilution of 10-7. Column A5-C5 contains 50 microliters of a 1% CRBC solution and 50 
microliters of allantoic fluid from the set of eggs infected with a dilution of 10-8  Column 
A6-C6 contains 50 microliters of 1% CRBC solution and 50 microliters of control 
allantoic fluid that was not infected with virus.  Rows F through H were used to verify the 
titer of A/WSN/33.  Columns 7A-7D, 8A-8D, 9A-9D, 10A-10D, 11A-11D, and 12A-12D  
were not used.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
             
 
            
 1 2 3 4 5 6 7 8 9 10 11 12 
 10-4 10-5 10-6 10-7 10-8 control       
A       X X X X X X 
B       X X X X X X 
C       X X X X X X 
D       X X X X X X 
E 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 1:8192 1:16384 1:32768 
F             
G             
H             
Figure 7. The plate design for the determination of EID of propagated 
A/Memphis/102/72. The first column from A1-C1 contains 50 microliters of a 1% CRBC 
solution and 50 microliters of allantoic fluid from the set of eggs infected with a dilution 
of 10-4. Column A2-C2 contains 50 microliters of a 1% CRBC solution and 50 
microliters of allantoic fluid from the set of eggs infected with a dilution of 10-5. Column 
A3-C3 contains 50 microliters of a 1% CRBC solution and 50 microliters of allantoic 
fluid from the set of eggs infected with a dilution of 10-6. Column A4-C4 contains 50 
microliters of a 1% CRBC solution and 50 microliters of allantoic fluid from the set of 
eggs infected with a dilution of 10-7. Column A5-C5 contains 50 microliters of a 1% 
CRBC solution and 50 microliters of allantoic fluid from the set of eggs infected with a 
dilution of 10-8. Column A6-C6 contains 50 microliters of 1% CRBC solution and 50 
microliters of control allantoic fluid that was not infected with virus.  Rows F through H 
were used to verify the titer of A/Memphis/102/72.  Columns 7A-7D, 8A-8D, 9A-9D, 
10A-10D, 11A-11D, and 12A-12D  were not used. 
 
 
1.1.5 Separation of peripheral blood mononuclear cells  
Whole human blood was collected via venupuncture in heparinized Vacu-Jet® tubes. 
Histopaque 1077 (Sigma-Aldrich) was aliquoted by amounts of 3 and 15 mL into sterile 
conical tubes, and stored at -20°C. Before use, tubes were thawed and kept at room 
temperature. Three mL of whole blood was carefully layered on top of the Histopaque. 
Each tube was then centrifuged for 30 minutes at room temperature at 1600 RPM. The 
plasma layers were then discarded, and the peripheral blood mononuclear cell (PBMC) 
layers were collected, and resuspended in cold 10 mL 5% FCS in RPMI.  The cells were 
rinsed 3X at 1200 RPM for 10 minutes with 10 mL 5% FCS in RPMI. After the final 
rinse, the cells were resuspended in 5 mL 5% FCS in RPMI and quantified. Fifty 
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microliters of cell suspension was added to 445 microliters of 5% FCS in RPMI. An 
additional 5 microliters of trypan blue was added. Cells were quantified using a 
hemacytometer and light microscope. Cells were counted three times, and then averaged. 
The average was then multiplied by 2X the dilution factor and them by 10,000. This 
provided the concentration of cells per milliliter.  
 
1.1.6 Fluorescence microscopy 
 
Whole human blood was collected via venupuncture in heparinized Vacu-Jet® tubes  
(Becton-Dickinson). At the time of use, tubes containing Histopaque 1077 (Sigma- 
Aldrich) were thawed and kept at room temperature. Three mL of whole blood was  
carefully layered on top of the Histopaque under sterile conditions. Each tube was then  
centrifuged for 30 minutes at room temperature at 1600 RPM. 
 
The plasma layers were then discarded, and the PBMC layers were collected and  
resuspended in cold 10 mL 5% FCS in RPMI.  The cells were rinsed 3X at 1200 RPM for  
10 minutes with 10 mL 5% FCS in RPMI. After the final rinse, the cells were  
resuspended in 5 mL 5% FCS in RPMI and quantified. Fifty microliters of cells  
suspension was added to 445 microliters of 5% FCS in RPMI. An additional 5  
microliters trypan blue was added. Cells were quantified using a hemacytometer and  
light microscope. Cells were counted three times, and then averaged. This provided the  
concentration of cells per milliliter. Peripheral blood mononuclear cells were  
quantified and subsequently tagged with fluorescent biotinylated antibiodies  
(eBioscience). Markers included anti-human CD4, CD14, CD21, CD40, and a rat isotype  
control.  PBMC were aliquoted into 5 Eppendorf tubes suspended in 5% FCS in RPMI  
with 0.5 mM EDTA. 
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The antibodies were diluted in an amount of 1 microgram per million cells in 5% FCS in  
RPMI with 0.5 mM EDTA, including the secondary antibody Streptavidin-FITC. Cells  
were pelleted at 5000 RPM for 30 seconds at room temperature and resuspended in the  
appropriate antibody dilutions. The cells were then incubated on ice for 30 minutes with  
gentle agitation every 10 minutes, and then rinsed three times using 500 microliters of  
5% FCS 0.5 mM EDTA in RPMI. The cells were then resuspended in the secondary  
antibody dilutions (50 microliters per marker).  The cells were then incubated again for  
30 minutes on ice in dark conditions. After incubation, all cells were rinsed again three  
times with 500 microliters 5% FCS in RPMI with 0.5 mM EDTA each time and then  
fixed with 1% paraformaldehyde and stored at 4°C in dark conditions.   
 
1.1.7 Flow cytometry 
 
Whole human blood was collected via venipuncture in heparinized Vacu-Jet® tubes.  
Fifteen mL whole blood was layered on top of 15 mL sterile Histopaque 1077 (Sigma- 
Aldrich) warmed to room temperature. Each blood suspension was then centrifuged for  
30 minutes at room temperature at 1600 RPMs. The plasma layers were then discarded, 
 and the PBMC layers were collected and resuspended in cold 10 mL 5% FCS in RPMI.   
The cells were rinsed three times at 1200 RPM for 10 minutes with 10 mL 5% FCS in  
RPMI. After the final rinse, the cells were resuspended in 5 mL 5% FCS in RPMI and  
quantified. Fifty microliters of cell suspension was added to 445 microliters of 5% FCS  
in RPMI. An additional 5 microliters trypan blue was added. Cells were quantified using  
a hemacytometer and light microscope. Cells were counted three times, and then  
averaged. This provided the concentration of cells per milliliter.  
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Cells were subsequently stained with the following FITC conjugated antibodies: CD4,  
CD4, CD19, and rat isotype control. Cells were kept on ice while the antibodies were  
diluted in 5% FCS 0.5 mM EDTA RPMI. The amount of cells used per antibody totaled 5  
x 105. The cells were aliquoted into Eppendorf tubes, and pelleted at 5000 RPM for 30  
seconds and resuspended in 50 microliters of antibody dilution. The cells were then  
incubated on ice in dark conditions. Each sample was agitated every 10 minutes to ensure  
antigen-antibody contact. At the end of incubation each sample was rinsed 3 times in 500  
microliters 5% FCS 5 mM EDTA in RMPI. After the final rinse each sample was  
resuspended in 500 microliters 1% paraformaldehyde and stored at 4°C in darkness.  
 
 
1.1.8 Identification of CD11c and CD14 positive cells from human blood 
Whole human blood was collected via venupuncture in heparinized Vacu-Jet® tubes.  
Whole blood was layered onto 15 mL sterile Histopaque 1077 tubes (Sigma-Aldrich)  
under sterile conditions and warmed to room temperature. Each blood suspension was  
then centrifuged for 30 minutes at room temperature at 1600 RPM. The plasma layers  
were then discarded, and the PBMC layers were collected and resuspended in cold 10 mL  
5% FCS in RPMI.  The cells were rinsed three times at 1200 RPM for 10 minutes with 10  
mL 5% FCS in RPMI. After the final rinse the cells were resuspended in 5 mL 5% FCS  
in RPMI and quantified. Fifty microliters of this cell suspension was added to 445  
microliters of 5% FCS in RPMI, and additional 5 microliters of Trypan blue was added.  
Cells were quantified using a hemacytometer and light microscope. This provided the  
concentration of cells per milliliter.  
 
The cells were subsequently pelleted and resuspended in FITC conjugated CD11c  
antibody, FITC conjugated CD14, and biotinylated rat isotype control. All antibodies  
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were diluted in 5% FCS in RPMI. The cells were incubated for 30 minutes on ice. After  
incubation, the cells were rinsed three times with 5 mL cold 5% FCS in RPMI.  After the  
third rinse the samples that were treated with FITC CD11c and FITC CD14 were  
resuspended in 250 microliters 1% paraformaldehyde. The sample treated with  
biotinylated rat isotype control antibody was resuspended in diluted FITC-Streptavidin  
antibody. The sample was kept on ice in dark conditions for 30 minutes. After incubation,  
the cells were rinsed with 5 mL cold 5% FCS in RPMI.  After the third rinse the sample  
was resuspended in 250 microliters 1% paraformaldehyde and stored at 4°C in dark  
conditions.  
 
1.1.9 Enrichment of monocytes using magnetic bead separation 
 
Whole human blood was collected via venupuncture in heparinized Vacu-Jet® tubes.  
Samples of whole blood were layered onto 15 mL sterile Histopaque 1077 tubes under  
sterile conditions (Sigma-Aldrich) , and warmed to room temperature. Each blood  
suspension was then centrifuged for 30 minutes at room temperature at 1600 RPM. The  
plasma layers were then discarded, and the PBMC layers were collected and resuspended  
in cold 10 mL 5% FCS in RPMI.  The cells were rinsed three times at 1200 RPM for 10  
minutes with 10 mL 5% FCS in RPMI. After final rinse, the cells were resuspended in 5  
mL 5% FCS in RPMI and quantified. Fifty microliters of cells suspension was added to  
445 microliters of 5% FCS in RPMI. An additional 5 microliters trypan blue was added.  
Cells were quantified using a hemacytometer and light microscope. Cells were counted  
three times, and then averaged. This provided the concentration of cells per milliliter.  
 
Biotinylated CD14 antibody was diluted in 5% FCS in RMPI and kept on ice. The total 
 number of PBMC isolated was pelleted and resuspended in the diluted antibody and  
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incubated on ice for 30 minutes.  Streptavidin beads (Miltenyi-Biotect) were diluted in  
cold 0.5% BSA solution and kept on ice. After incubation, cell suspension was pelleted,  
and resuspended in the streptavidin bead dilution. The cells were incubated on ice for 30 
 minutes.  After incubation, 10 mL of cold 0.5% BSA solution was added to the cell  
suspension, and was centrifuged for 10 minutes at 1000 RPM. After centrifugation, the  
supernatant was removed, and the cells were resuspended in 500 microliters of separation  
buffer.  
 
A magnetic column apparatus was prepared and kept at -20°C until use.  A sterile column 
 was opened and rinsed with 1 mL cold separation buffer.  Five hundred microliters of  
cell suspension was then added to the top of the column and allowed to flow through the  
column. All buffer filtered through was collected in a sterile tube. After all cell  
suspension was filtered, 1 mL of additional separation buffer was added to rinse the  
column. Five milliliters of cold 5% FCS in RPMI was added to the cell suspension.  
Another 1 mL of cold separation buffer was added to the column and quickly plunged.   
All fluid was collected in another sterile conical tube. Five mL cold 5% FCS in RPMI  
was added to this tube.  
 
FITC anti CD11c antibody was diluted in 5% FCS in RMPI and stored on ice in dark  
conditions. Cells in both conical tubes were pelleted and resuspended in antibody  
dilution. Both samples were incubated for 30 minutes on ice in dark conditions. After  
incubation, cells were rinsed three times using 500 microliters 5% FCS in RMPI. After  
final rinse, the pellets were resuspended in 250 microliters of a 1% paraformaldehyde  
solution. The samples were stored at 4°C in dark conditions. 
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1.1.10 Propagation of dendritic cells derived from monocytes 
Whole human blood was collected via venupuncture in heparinized Vacu-Jet® tubes. 
Under sterile conditions, amounts of whole blood were layered onto 15 mL sterile 
Histopaque 1077 tubes (Sigma-Aldrich) warmed to room temperature. Each blood 
suspension was then centrifuged for 30 minutes at room temperature at 1600 RPM. The 
plasma layers were then discarded, and the PBMC layers were collected, and resuspended 
in cold 10 mL 5% FCS in RPMI.  The cells were rinsed 3X at 1200 RPM for 10 minutes 
with 10 mL 5% FCS in RPMI. After final rinse, the cells were resuspended in 5 mL 5% 
FCS in RPMI and quantified. Fifty microliters of cells suspension was added to 445 
microliters of 5% FCS in RPMI. An additional 5 microliters trypan blue was added. Cells 
were quantified using a hemacytometer and light microscope. Cells were counted three 
times, and then averaged. This provided the concentration of cells per milliliter.  
 
Biotinylated CD14 antibody was diluted in 5% FCS in RMPI and kept on ice. The total 
number of PBMC isolated was pelleted and resuspended in the diluted antibody. A small 
amount of cells was separately tagged for with FITC-CD14 using the protocol in section 
1.1.6. The sample was read the following day using flow cytometry.  The cells 
suspension was then incubated on ice for 30 minutes.  Streptavidin beads (Miltenyi-
Biotec) were diluted in cold 0.5% BSA solution and kept on ice. After incubation, the cell 
suspension was pelleted and resuspended in the streptavidin bead dilution. The cells were 
incubated on ice for 30 minutes.   
 
After incubation, 10 mL of cold 0.5% BSA solution was added to the cell suspension and 
was centrifuged for 10 minutes at 1000 RPM. After centrifugation the supernatant was 
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removed and the cells were resuspended in 500 microliters of separation buffer. A 
magnetic column apparatus (Miltenyi Biotech) was prepared and kept at -20°C until use.  
A sterile column was opened and rinsed with 1 mL of cold separation buffer.  Five 
hundred microliters of cell suspension was then added to the top of the column, allowed 
to flow through the column, and collected in a sterile tube. After all cell suspensions were 
filtered 1 mL of additional separation buffer was added to rinse the column. Five mL of 
cold 5% FCS in RPMI was added to the cell suspension. Another 1 mL of cold separation 
buffer was added to the column and quickly plunged. The fluid was collected in another 
sterile conical tube. Five milliliters of cold 5% FCS in RPMI was added to this tube. 
Cells that were collected last from the column were resuspended in 15 mL dendritic cell 
culture medium. In a sterile 12-well tissue culture plate, the cell suspension was 
distributed to 9 wells. The plate was then incubated for 6 days at 37°C and 5% humidity. 
On the 6th day of incubation the cell suspensions were collected and pooled in a 50 mL 
conical tube. Each well of the plate was rinsed 3 times with 1 mL 5% FCS in RPMI. The 
cells were then tagged with FITC-CD14 and CD11c according to protocol 1.1.6. The 
samples were processed the following day. 
 
 
1.2 Results 
 
 
1.2.1 Propagation of influenza virus in embryonated chicken eggs 
Embryonated chicken eggs were infected with influenza strains A/Memphis/102/72  
(H3N2) and A/WSN/33 (H1N1).  Allantoic fluid was collected after 30 minutes of  
incubation at -20°C and clarified via centrifugation. A hemagglutination titration was run  
to quantify virus particles. After titration plates were prepared and incubated at room  
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temperature for 30 minutes, each column was observed for hemagglutination.  
 
The strain A/Memphis/102/72 was found to have a HAU of 1:512 (Figure 8). The  
last column (A12-H12) was used as an internal control, it received only BSA solution  
and CRBC solution, and so was negative for agglutination.  Columns 1-9 show positive  
agglutination, ending with the dilution of 1:512. Columns 10 (1:1096) and 11 (1:2192)  
were negative for agglutination.  Thus, the propagated virus strain A/Memphis/102/72  
(H3N2) was shown to have a HAU of 1:512.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1096 1:219
2 
Control 
A + + + + + + + + + - - - 
B + + + + + + + + + - - - 
C + + + + + + + + + - - - 
D + + + + + + + + + - - - 
E + + + + + + + + + - - - 
F + + + + + + + + + - - - 
G + + + + + + + + + - - - 
H + + + + + + + + + - - - 
Figure 8. Results of A/Memphis/102/72 HAU titration.  Columns 1-9 showed 
agglutination. Columns 10 and 11 demonstrated no agglutination. Column 12 received no 
virus, and was negative for agglutination.  
 
 
The strain A/WSN/33 was found to have a HAU of 1:256 (Figure  9). The last column  
(A12-H12) was used as an internal control, and received only BSA solution and CRBC  
solution and was negative for agglutination.  Columns 1-8 show positive agglutination,  
ending with the dilution of 1:256. Columns 9, (1:512), 10 (1:1096) and 11 (1:2192) were  
negative for agglutination.  Thus, the propagated virus strain A/WSN/33 (H1N1) was  
shown to have a HAU of 1:256. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1096 1:2192 Control 
A + + + + + + + + - - - - 
B + + + + + + + + - - - - 
C + + + + + + + + - - - - 
D + + + + + + + + - - - - 
E + + + + + + + + - - - - 
F + + + + + + + + - - - - 
G + + + + + + + + - - - - 
H + + + + + + + + - - - - 
Figure 9. Results of A/WSN/33 HAU titration.  Columns 1-8 showed agglutination. 
Columns 9-11 demonstrated no agglutination. Column 12 received no virus, and was 
negative for agglutination.  
 
 
1.2.2  Determining the egg infectious dose of propagated virus 
Egg infectious dose cultures were determined using 10 day old embryonated chicken  
eggs and propagated influenza from the experiment in 1.2.1. Dilutions were made of each  
virus strain and eggs were infected for 48 hours. After incubation eggs were kept at  
-20°C. Allantoic fluid from the eggs was collected and clarified via centrifugation.  
Ninety-six well plates were prepared according to the protocol used in 1.1.3. The plates  
were incubated at room temperature for 30 minutes and were then observed for  
agglutination.  As seen in Figure 10, A/Memphis/102/72 was shown to have an egg  
infectious dose of 107 EID50%. Columns containing allantoic fluid from eggs treated  
with dilutions less than 10-7 were shown to be positive for agglutination. This indicates  
that eggs inoculated with dilutions 10-7 or less were infected. There was no infection in  
eggs treated with dilution 10-8. 
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1 2 3 4 5 6 7 8 9 10 11 12 
10-4 
 
10-5 10-6 10-7 10-8 Control 
      
+ + + + - - X X X X X X 
+ + + + - - X X X X X X 
+ + + + - - X X X X X X 
      X X X X X X 
1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 1:8192 1:16384 1:32768 
+ + + + + + - - - - - - 
+ + + + + + - - - - - - 
+ + + + + + - - - - - - 
Figure 10. H3N2 EID 50% titration results.  The top portion of the plate demonstrates 
agglutination in the first 4 columns. The column that contained virus diluted to 10-8 
demonstrated no agglutination. The control wells were also negative for agglutination. 
The repeated titration showed the virus to have an HAU of 512. Columns 7 through 12 
were unused (marked by an X) in the top half the plate. 
 
 
A/WSN/33 was shown to have an EID50% of 10-5 and an HAU of 1:256. As seen in 
Figure 11, the first 2 columns should to be positive for agglutination. The columns 
containing allantoic fluid from eggs treated with dilutions 10-6 – 10-7 were negative for 
agglutination. The control column was negative for agglutination as well. The stock virus 
from both strains was kept at –80°C for future experiments. 
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1 2 3 4 5 6 7 8 9 10 11 12 
10-4 10-5 10-6 10-7 10-8 Control 
      
+ + - - + - X X X X X X 
+ + - - + - X X X X X X 
+ + - - + - X X X X X X 
      X X X X X X 
1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 1:8192 1:16384 
+ + + + + + - - - - - - 
+ + + + + + - - - - - - 
+ + + + + + - - - - - - 
Figure 11. A/WSN/33 EID and titration results.  The top portion of the plate demonstrates 
agglutination in the first 2 columns. Dilutions 10-6 and 10-7 were negative for 
agglutination. The column that contained virus diluted to 10-8 was positive for 
agglutination. The control wells were negative for agglutination.  The repeated titration 
reaffirmed that the propagated virus has an HAU of 256. Columns 7 through 12 were 
unused (marked by an X) in the top half the plate. 
 
 
1.2.3 Separation of peripheral blood mononuclear cells  
Human peripheral blood mononuclear cells were separated from whole blood using the 
 protocol described in 1.1.4. The goal of these experiments was to optimize the technique  
of separation, and to obtain a consistent amount of cells. Two different types of rinsing  
reagents were used. From this, it was determined that using 5% fetal calf serum diluted in  
RMPI medium yielded the higher amount of cells after all washing steps had been  
completed. It was determined that from 3 mL of whole blood, more than a million  
PMBC could be obtained as seen in Table 1.  
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Table 1. The results of the initial PMBC isolation. 
Experiment 
Date 
Blood Volume [PBMC] Total cells 
    
6/13/07 3 mL 6.5 x 10^6 1.90 x 10^7 
6/20/07 3 mL 6.2 x 10^6 1.86 x 10^7 
6/29/07 3 mL 4.8 x 10^6 1.44 x 10^7 
7/2/07 3 mL  6.8 x 10^6 2.00 x 10^7 
7/9/07 3 mL  3.0 x 10^6 9.00 x 10^6 
7/12/07 3 mL 1.9 x 10^6 5.7 0x 10^6 
 
 
1.2.4 Fluorescence microscopy 
 
After separation of PBMC from whole blood had been optimized, the cells were tagged  
with various markers and then observed under fluorescence microscopy. These  
experiments determined if certain cell populations could accurately be quantified using  
fluorescent antibodies. These experiments were used to optimize flow cytometry analysis. 
 Using the protocol listed in 1.1.6, cells were separated and stained. Images were taken  
using both brightfield microscopy and fluorescence microscopy. Cells were enumerated  
in both fields to determine the positive fluorescence in each sample.  
 
Table 2. Results from quantifying PBMC tagged with fluorescent antibodies viewed 
under 400X magnification.  
Antibody Total Cells Positive 
Cells 
Percentage of Positive 
Cells 
Expected Percentage 
 
    
Isotype 116 4 3% 0% 
CD4 107 20 19% 25% 
CD14 106 10 9% 3-7% 
CD40 125 34 27% 23-33% 
CD21 113 34 30% 18-43% 
 
 
As seen in Table 2, cells were tagged with 5 markers and quantified. The rat isotype  
control demonstrated a 3% positive population of cells. A low percentage of cells are  
expected with a sample treated with this marker which was used as the internal control in  
these sets of experiments. The sample of cells treated with anti-CD4 antibodies indicated  
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a positive population of cells amounting to 19%. In a healthy individual, the number of  
CD4 positive cells is close to 25%. Samples treated with CD14 and CD40 were within  
range of normal levels to be expected. Cells stained with marker CD21 showed a positive  
population of 30%, which is also within range. All antibodies used in these experiments  
were purchased from eBioscience. Below are shown typical results obtained after  
optimization of the technology. 
  
Figure 12. The images above demonstrate peripheral blood mononuclear cells stained 
with a rat isotype control antibody conjugated to FITC-Streptavidin. The left image 
shows cells under 400X brightfield microscopy. The image to the right demonstrates no 
fluorescent binding. This sample served as an internal control. 
 
The biotinylated antibody Rat IgG2a Isotype control is used as an isotype control  
immunoglobulin. It is expected that a sample of human PBMC treated with this antibody  
would show a minimal population of cells, if any. A population higher than 10% would  
indicate a poor protocol. As shown in Figure 12, no cells are positive for fluorescence.  
Cells are shown however under brightfield microscopy.  
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Figure 13. The images above demonstrate peripheral blood mononuclear cells stained 
with CD4 FITC. The left image shows the cells under 400X brightfield microscopy. The 
image to the right shows a group of cells positive for CD4 viewed under 400X UV. 
 
 
The CD4 marker is expressed on many cells including most T-cells, and a minute  
population of T-helper cells. It can also be found in low levels on monocytes. CD4 is the  
main receptor for the human immunodeficiency virus as well. As seen in Figure 13, the  
cells in the PMBC population positive for CD4 were visible via FITC. Figure 13 shows  
cells treated with CD4 in brightfield. In that same view (right), under fluorescence  
microscopy, only 3 cells are seen. These 3 cells enclosed in the red box were considered  
positive for expression of marker CD4. 
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Figure 14. The images above demonstrate PBMC stained with CD14 FITC. The left 
image shows cells under 400X brightfield microscopy. The image to the right shows a 
group of cells positive for CD14 viewed under 400X UV. 
 
 
The CD14 marker is expressed generally on monocytes as well as macrophages and some  
dendritic cells. As seen in Figure 14, the cells in the PBMC population positive for CD14  
were visible via FITC. Figure 15 shows cells treated with CD14 in brightfield. In that  
same view (right) under fluorescence microscopy only 3 cells could be seen, these  
(enclosed in the red box) were considered positive for expression of marker CD14.  
 
 Figure 
15. The images above demonstrate more PMBC stained with PE conjugated CD21 
antibody. The left images show cells under 400X brightfield microscopy. The images to 
the right demonstrate CD21 positive cells under fluorescence microscopy. 
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CD21 is a marker expressed by mature B cells, follicular dendritic cells and a small  
population of epithelial cells. This marker also serves as a receptor for complement  
component C3d and Epstein-Barr virus. CD21 is also involved in B cell activation by T  
cells. Demonstrated in Figure 15, images using brightfield and fluorescence microscopy  
show cells positive for expression of CD21. Cells positive for fluorescence are seen in the  
images to right enclosed in red boxes. Those same cells are viewed with brightfield  
microscopy on the left in Figure 15.  
 
 
Figure 16. The images above demonstrate more PBMC stained with FITC conjugated 
CD40 antibody. The left images show a group of cells enclosed 400X brightfield 
microscopy. The images to the right show the same population of enclosed cells as CD40 
positive. 
 
 
The biotinylated anti-CD40 antibody is expressed on several populations of cells. It is  
primarily expressed on B lymphocytes, and follicular dendritic cells. It can be expressed  
at low levels on thymic epithelium, and a subset of peripheral T cells. Engagement of  
CD40 with CD40L, in addition with IL-4, acts to ensure B cell development and  
maturation by initiating Ig isotype switching. It also serves to protect B cells from surface  
Ig-induced apoptosis and promotes proliferation. CD40 has also been found to play a role 
 in cross-talk between B cells and T cells, and costimulation and immune regulation.  
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Figure 16 shows images taken under brightfield and fluorescence microscopy using an  
anti-CD40 antibody. CD40 positive cells are shown enclosed in red boxes to the right.  
Those same cells can be seen in the images to the left under brightfield microscopy.  
 
1.2.5 Flow cytometry 
In order to conduct the crucial experiments in this thesis, the technique of flow cytometry  
had to be optimized. The objective of these experiments was to successfully stain PBMC  
with selected anti-marker antibodies. Once stained, these cells would be analyzed using  
flow cytometery technology. After staining, cells were fixed with paraformaldehyde and  
incubated with the selected antibody and kept at 4°C in dark conditions. These conditions  
are necessary in order to preserve fluorescence until reading the results using flow  
cytometery technology. Samples were generously analyzed at Marquette General  
Hospital.  Below are shown typical results obtained after optimization of the technology.  
 
1.2.5.1 Determination of flow cytometry using an irrelevant antibody 
Baseline readings were done using the irrelevant antibody, a biotinylated rat isotype  
antibody, that served as a negative control. Figure 17 shows the output of flow  
cytometery using the irrelevant antibody, whereby positive cells for the rat isotype  
antibody were found, indicating that flow cytometry outputs for the other samples are  
reliable and valid. 
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Figure 17. The above diagrams represent the flow cytometery analysis for the cell sample 
treated with the irrelevant antibody. The above diagram to the left is the output of the side 
scatter (SS Log) versus fluorescence intensity (Iso-fitc).  The box does not show a 
positive cell population, which is to be expected, as this sample was negative. The 
diagram to the right shows the output for the number of cells versus fluorescence (Iso-
fitc).  
 
 
1.2.5.2 Determination of flow cytometry using an anti-CD19 antibody 
Samples stained with biotinylated antibody CD19 were also processed through flow  
cytometery. The scatters seen in Figure 18 show the intensity of the cells positive for  
fluorescence, as well as how many cells were positive for the CD19 marker. One-hundred  
thousand cells were processed in the sample. A low percentage of those, were found to be  
CD19 positive. CD19 is commonly found on B cells, at any stage of maturation.  
Follicular dendritic cells also express CD19 but they are not found in blood. 
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Figure 18. Flow cytometry analysis for the cell sample treated with CD19. The diagram 
on left is the output of side scatter (SS Log) versus fluorescence intensity (CD19-fitc). 
The cells within the box are considered positive for the expression of CD19. The diagram 
on the right is the output of the number of cells versus fluorescence intensity (CD19-fitc). 
 
 
1.2.5.3 Determination of flow cytometry using an anti-CD45 antibody 
The antibody CD45 specifically binds to leukocyte common antigens (LCA) that are  
expressed on all hematopoietic cells, except for platelets and erythrocytes. This antigen is  
important in the activation of lymphoctyes. CD45 is expressed prolifically on many cells,  
with the expectation that a sample of peripheral blood mononuclear cells would mostly  
be CD45 positive. Figure 19 shows that almost all cells processed via flow cytometry 
were CD45 positive. 
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Figure 19. Flow cytometery analysis for the cell sample treated with CD45 antibody. The 
diagram on left is the output of side scatter (SS Log) versus fluorescence intensity 
(CD45-fitc). The cells within the box were CD45 positive. The diagram on the right is the 
output of the number of cells versus (CD45-fitc).  
 
 
1.2.5.4 Determination of flow cytometry using an anti-CD4 antibody 
One-hundred thousand cells were stained with CD4 antibody, and roughly a third of these  
cells were found to be CD4 positive (Figure 20), a quantification that is within range of  
the normal CD4 T cell population in circulation.   
 
 
 
 
Figure 20. Flow cytometery analysis for the cell sample treated with CD4 antibody. The 
diagram on left is the output of side scatter (SS Log) versus fluorescence intensity (CD4-
fitc). The cells in the box are CD4 positive. The diagram on the right is the output of the 
number of cells versus fluorescence intensity (CD4-fitc). 
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1.2.5.5 Determination of flow cytometry using an anti-CD14 antibody 
There is a very low population of dendritic cells in circulation in the blood. To propagate  
dendritic cells from humans, monocytes from blood must be isolated and stimulated for  
DC maturation.  Monocytes in the blood can amount from 2-10% in a healthy individual.  
The basis for these sets of experiments was to quantify the percentage of monocytes in  
the donors blood. CD14 is mainly expressed on monocytes and dendritic cells.  
 
 
Figure 21. Flow cytometery analysis for the samples stained with CD14. The diagram on 
left is the output of side scatter (SS Log) versus fluorescence intensity (CD14-fitc). The 
cells in the box are CD14 positive. The diagram to the right shows the output for the 
number of cells versus fluorescence intensity (CD14-fitc).  
 
Figure 21 shows a very small percentage of cells stained with the CD14 antibody were  
identified as positive, as would be expected because very few cells in circulation would  
display the CD14 marker. When stimulated, monocytes from blood mature into dendritic  
cells. There is a dramatic increase in CD14 marker expression, as well as CD11. This  
increased expression of markers indicates maturation has occurred in the population.  
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1.2.5.6 Determination of flow cytometry using an anti-CD11c antibody 
Another molecule of interest in relation to monocytes in the blood is marker CD11c.  
This molecule is also mainly found on monocytes and dendritic cells. Thus, it was  
critical to determine baseline numbers in the donor’s blood for the two markers.  
 
 
Figure 22. Flow cytometery analysis for the samples stained with CD11c. Cells 
displaying CD11c mainly include monocytes, the cell of interest in this experiment. The 
diagram on left is the output of side scatter (SS Log) versus fluorescence intensity 
(CD11c-fitc). The cells in the box are considered CD11c positive. The diagram to the 
right shows the output for the number of cells versus side fluorescence intensity (CD11c-
fitc).  
 
Figure 22 shows the scatter plots for the cell sample stained with CD11c. There are very  
few monocytes in circulation. Thus, it is expected that this sample would not demonstrate  
a high population of CD11c positive cells. 
 
1.2.6 Enrichment of monocytes using magnetic bead separation 
Specific cell populations can be enriched using magnetic beads. Large amounts of  
dendritic cells were needed,  but this population is in low frequency in the blood.  
Monocytes from blood can be stimulated to mature into dendritic cells, if exposed to  
certain cytokine cues. Therefore, monocytes were isolated from blood and cultured in  
vitro to differentiate in dendritic cells. The separation of the monocytes from peripheral  
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blood mononuclear cells needed to be optimized. In these experiments, PBMC were  
incubated with biotinylated CD14 antibody, and subsequently with streptavidin  
conjugated magnetic beads. Subsequently, the cells were then run through a magnetic  
column. The cells expressing the CD14 marker remained in the column, while the CD14  
negative cells were flushed through. The cell population remaining in the column would  
then be enriched with marker CD11c. The cell population that passed through the column  
would be depleted of the CD11c marker.  
 
Table 3. Two samples of cells were processed via flow cytometery to determine 
monocyte enrichment. The separated population was collected after all cell suspension 
was run through the column. This population would be considered CD11c-enriched. The 
sample not separated shows a CD11c+ population of 6.05%. After the cells were 
separated there was an increase in CD11c+ cells.  
 Total Cells counted CD11c + Cells % CD11c + Cells 
Sample    
    
Separated 5317 1399 26.31 
No separation 10000 6052 6.05 
 
 
Table 3 shows that a sample of cells was not magnetically separated. The amount of cells  
in this population was 6.05%. This provides a baseline for the amount of cells expressing  
CD11c in the blood. Figure 23 shows that the scatter plots for this sample also depicted  
the low population occurring in circulation. 
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Figure 23. Flow cytometery analysis for the cell sample that was not magnetically 
separated. These cells were stained with anti-CD11c antibody, and read using flow 
cytometry. The diagram on left is the output of side scatter versus (SS Log) fluorescence 
intensity (CD11c-fitc). The diagram to the right shows the output for the number of cells 
versus fluorescence intensity (CD11c-fitc).  
 
Cells labeled with CD14 were bound to magnetic beads with anti-CD14 antibodies.  
Therefore when the sample was run through the column, cells positive for the CD14  
marker were retained, while the cells in the CD14 negative population were not. Figure  
24 shows that the labeled cells (CD14 enriched) had a higher percentage of CD11c  
positive cells, as to be expected. It is also noteworthy that only a very small population of  
CD11c cells was able to be quantified, which is to be expected because there are  
normally very few monocytes in circulation in the blood.  
 
 
 Figure 24. Flow cytometry analysis for the cell sample that was magnetically separated 
and stained for CD11c. This sample represents the cells remaining in the column after 
separation, or the CD14 positive cells. The diagram on left is the output of side scatter 
versus fluorescence intensity (CD11c-fitc). 
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1.2.7 Production of monocyte-derived dendritic cells 
Successful propagation of monocyte-derived dendritic cells can be demonstrated with an  
increase of the marker CD14.  As seen in Table 4, an initial sample of cells later  
stimulated with cytokines was stained with molecule CD14. This initial enumeration of  
CD14 positive cells provided a baseline. After culture with cytokines, it is expected that a  
sample of cells stained again with CD14 antibody would show a higher percentage.   
 
Table 4. Before monocytes were incubated with cytokines GM-CSF and IL-4, cells were 
tagged with FITC-conjugated antibodies CD14 and CD11c (specific for monocytes and 
dendritic cells). After a 6 day incubation period with cytokine treatment, cells were 
tagged again with CD14 and CD11c to note an enrichment of the population. Figure 27 
shows the initial sample of cells stained with CD14 antibody with a very low percentage 
of positive cells. This is expected, because the cells had not yet been exposed to 
stimulatory cytokines in vitro. 
 
Total Cells Total FITC + 
Cells  
Total Percentage FITC + Cells 
MARKER    
Before Cytokine Treatment 
   
CD14 100000 6064 6.06 
    
After Cytokine Treatment 
   
CD14 54337 18938 34.85 
 
 
Figure 25 demonstrates a smaller population of CD14 positive cells. This is to be  
expected because the cells had been stained before cytokine treatment was given. An  
increase in CD14 expression is only expected to be observed after the cells had been  
treated with IL-4 and GM-CSF. 
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Figure 25. Flow cytometery scatter plots of cells initially stained with CD14 antibody. 
These cells had not yet been incubated with cytokines that would stimulate dendritic cell 
maturation. A small subset of cells from the sample expressed the molecule CD14. The 
diagram on left is the output of side scatter (SS Log) versus fluorescence intensity 
(CD14-fitc). The diagram to the right shows the output for the number of cells versus 
fluorescence intensity (CD14-fitc).  
 
Figure 26 shows the flow cytometery analysis for cells stained after incubation with  
cytokines. It is demonstrated here that there was a higher percentage of cells expressing  
the CD14 molecule. With this increase, it can be concluded that the monocytes separated  
with blood had successfully matured into dendritic cells.  
 
Figure 26. Flow cytometery scatter plots of cells stained with CD14 antibody after a 6-
day incubation with cytokines IL-4 and GM-CSF. After this incubation, a higher 
percentage of cells were expected to be CD14 positive. As shown, a higher percentage of 
cells cultured with the cytokine express the molecule. The diagram on the left is the 
output of side scatter (SS Log) versus fluorescence intensity (CD14-fitc). The diagram to 
the right shows the output for the number of cells versus fluorescence intensity (CD14-
fitc). 
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CHAPTER 2: Co-stimulatory surface molecule expression on human monocyte-
derived dendritic cells infected with two strains of influenza virus 
 
2.1 Materials/Methods 
Whole human blood was collected via venupuncture in heparinized Vacu-Jet® tubes.  
Under sterile conditions, whole blood was layered onto 15 mL sterile Histopaque 1077  
tubes (Sigma-Aldrich) warmed to room temperature. Each blood suspension was then  
centrifuged for 30 minutes at room temperature at 1600 RPM. The plasma layers were  
then discarded, and the PBMC layers were collected, and resuspended in cold 10 mL 5%  
FCS in RPMI.  The cells were rinsed 3X at 1200 RPM for 10 minutes with 10 mL 5%  
FCS in RPMI. After final rinse, the cells were resuspended in 5 mL 5% FCS in RPMI  
and quantified. Fifty microliters of cells suspension was added to 445 microliters of 5%  
FCS in RPMI. An additional 5 microliters trypan blue was added. Cells were quantified  
using a hemacytometer and light microscope. Cells were counted three times, and then  
averaged. The average was then multiplied by 2X the dilution factor and then by 10,000.  
This provided the concentration of cells per milliliter.  
 
Biotinylated CD14 antibody was diluted in 5% FCS in RMPI and kept on ice. The total  
number of PBMC isolated was pelleted, and resuspended in the diluted antibody. A small  
amount of cells was separately tagged with FITC-CD14 using the protocol in section  
1.1.6. The cell suspension was then incubated on ice for 30 minutes. The sample was  
read the following day using flow cytometery.    
 
Streptavidin beads (Miltenyi-Biotec) were diluted in cold 0.5% BSA solution and kept on  
ice. After incubation, cell suspension was pelleted, and resuspended in the streptavidin  
bead dilution. The cells were incubated on ice for 30 minutes.  After incubation, 10 mL  
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of cold 0.5% BSA solution was added to the cell suspension, and was centrifuged for 10  
minutes at 1000 RPM. After centrifugation, the supernatant was removed, and the cells  
were resuspended in 500 microliters of separation buffer. A magnetic column apparatus  
was prepared and kept at -20°C until use.  A sterile column was opened and rinsed with 1  
mL cold separation buffer.  Five hundred microliters of cell suspension was then added to  
the top of the column and allowed to flow through the column. All buffer that filtered  
through was collected in a sterile tube. After all cell suspension was filtered, 1 mL of  
additional separation buffer was added to rinse the column. Five mL of cold 5% FCS in  
RPMI was added to the cell suspension. Another 1 mL of cold separation buffer was  
added to the column and quickly plunged. All fluid was collected in another sterile  
conical tube. Five milliliters of cold 5% FCS in RPMI was added to this tube. 
 
 Cells that were collected last from the column were resuspended in 15 mL dendritic cell  
culture medium. In a sterile 12-well tissue culture plate, the cell suspension was  
distributed to 9 wells. The plate was then incubated for 6 days at 37°C 5% CO2. On  
the 6th day of incubation, the cell suspensions were collected and pooled in a 50 mL  
conical tube. Each well of the plate was rinsed 3X with 1 mL 5% FCS in RPMI. All  
contents were pooled, and then split into three sterile tubes in sterile conditions. Tube 1  
was pelleted  and resuspended in 7 mL 1X trypsin in RMPI, and put on ice. This tube  
served as the mock infected tube. This suspension was split into two tubes equally. Both  
tubes were pelleted. The first tube was resuspended in 1 mL undiluted A/WSN/33 (HAU 
 1:256) and 200 microliters 1X trypsin. The second tube was resuspended in 200 
 microliters A/WSN/33 (HAU 1:256) and 1.8 mL 1X trypsin. These cells were put on  
ice. 
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The third tube was pelleted, and resuspended. The contents were equally split into three  
tubes. All tubes were pelleted subsequently. The first tube was resuspended in a dilution  
of 1:10 A/Memphis/102/72 in 1X trypsin. The second tube was resuspended in a viral  
dilution of 1:100 in 1X trypsin. The final tube was resuspended in a 1:1000 dilution of  
the virus in 1X trypsin. All tubes were then gently agitated, and put in a 37°C water bath  
for 40 minutes. After incubation, 10 mL 10% FCS in RPMI was added to each tube. Each  
tube was pelleted, and resuspended in 5 mL 10% FCS in RPMI. Each infection was  
performed in a separate tissue culture plate for 4 hours at 37°C in 5% CO2 .  
 
After incubation, the contents from each plate were collected. The wells were rinsed 3X  
with 10% FCS in RMPI. The 3 treatments were then pelleted, and resuspended in  
eppendorf tubes, and rinsed again with 1 mL 10% FCS in RPMI. The cell suspensions  
were then split equally into 9 Eppendorf tubes per treatment. Antibodies rat isotype  
control, CD11b, CD40, CD86, MHC Class II, MHC Class I, and BAFF were diluted in  
5% FCS in RPMI accordingly, and kept on ice. Each tube was pelleted and resuspended  
in the appropriate antibody. The cell samples were resuspended in antibody, diluted and  
coded, as seen in Table 5.  
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Table 5. The table shows codes indicating what treatment each cell suspension received 
during the final experiment. Initially, two groups of cells were infected with two strains 
of influenza virus: A/WSN/33 and A/Memphis/102/72. A third group was mock infected 
with 1X trypsin. After incubation, the three groups were then split equally into 9 
Eppendorf tubes and stained with antibodies MHC Class II, MHC Class I, CD40, CD86, 
CD11b, BAFF, and an irrelevant rat isotype control. A total of 54 samples were prepared, 
and processing using flow cytometry. 
 
MHC Class II CD40 CD86 CD11b MHC Class I BAFF Rat 
A/WSN/33 
       
MOI 1  A1-1 A1-2 A1-3 A1-5 A1-6 A1-7 A1-9 
MOI 0.1 A2-1 A2-2 A2-3 A2-5 A2-6 A2-7 A2-9 
 
       
A/Memphis/102/72 
       
MOI 1 2-1 2-2 2-3 2-5 2-6 2-7 2-9 
MOI 0.1 3-1 3-2 3-3 3-5 3-6 3-7 3-9 
        
Mock-Infected        
 
C-1 C-2 C-3 C-5 C-6 C-7 C-9 
 
Each tube was incubated on ice at 4°C in dark conditions for 30 minutes. After  
incubation, each cell suspension was rinsed 3X with 5% FCS in RMPI. Upon final rinse,  
cell pellets were resuspended in 500 microliters 1% paraformaldehyde solution. The cells  
samples were stored at 4°C in dark conditions until processing.  
 
2.2 Results 
 
2.2.1 Rat isotype marker expression 
 
After infection each group was stained with an irrelevant antibody used in previous  
experiments in Chapter 1. Table 6 shows that cells infected with A/WSN/33 (MOI of 1  
and 0.1), and A/Memphis/102/72 (MOI of 1 and 0.1). A group of cells was also mock  
infected with diluted Trypsin in RPMI. After infection, each group of infected cells was 
 stained with a rat isotype control antibody, and fixed in 1% paraformaldehyde.  
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Table 6. Cells stained with a rat isotype control antibody. Two groups of cells were 
infected with A/WSN/33 MOI of 1 and 0.1 Another set of cells was infected with an 
A/Memphis/102/72 MOI of 1, and 0.1. The last group was mocked infected with 1X 
trypsin only. The second column shows the total amount of cells enumerated by the flow 
cytometry machine. The 3rd column shows the number of cells expressing the irrevelant 
rat marker. The far right column denotes the percentage of cells positive for expressing 
the irrelevant marker.  
Rat Isotype Control Total Cells Counted Marker + Cells % Marker + Cells 
    
A/WSN/33  
 
   
MOI 1 6934 4 0.06 
MOI 0.1 4907 4 0.08 
 
   
A/Memphis/102/72 
   
 
   
MOI 1 8487 4 0.05 
MOI 0.1 4346 4 0.09 
 
   
Mock Infected 
   
 
7991 10 0.13 
 
 
The group of cells infected with the viral strains A/WSN/33 and A/Memphis/102/72  
showed no marker expression of the rat isotype (Figures 27-31, Appendix A). This is to  
be expected, as this antibody is designed to act as an internal control. Cells containing  
fluorescent antibody would demonstrate background due to staining technique. Figure 31  
shows a small subset of cells that was mock infected was essentially negative for  
expression of the isotype marker indicating that there was no significant background due  
to staining technique, and validating of the results from the other samples.  
 
2.2.2 CD40 marker expression 
Groups of cells infected with A/WSN/33 (MOI of 1 and 0.1), A/Memphis/102/72 (MOI  
of 1, and 0.1) were stained with an antibody directed against the cellular marker CD40. A  
group of cells was also mock infected with diluted Trypsin and then stained with the  
antibody. The marker CD40 is expressed by B lymphocytes, follicular dendritic cells,  
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thymic epithelium, and a small subset of peripheral T cells. This marker serves to  
regulate B cell maturation and development by initiating antibody isotype switching. This  
marker stimulates proliferation in collaboration with chemokines such as IL-4, and  
protects B cells from apoptosis. CD40 is also crucial for the cross talk of other immune  
system players. Table 7 shows cells processed through flow cytometery quantified based  
on fluorescence.  
 
Table 7. Cells stained with CD40 antibody. Two groups of cells were infected with 
A/WSN/33 MOI of 1 and 0.1. A second set of cells was infected with an 
A/Memphis/102/72 MOI of 10, 1, and 0.1. The last group was mocked infected with 1X 
trypsin only. The second left column shows the total amount of cells enumerated by the 
flow cytometry machine. The middle column shows the number of cells expressing the 
CD40. The far right column denotes the percentage of cells positive for expressing the 
CD40 marker.  
CD40 Total Cells Counted Marker + Cells % Marker + Cells 
    
A/WSN/33  
 
   
MOI 1 33387 1607 4.81 
MOI 0.1 11075 84 0.76 
 
   
A/Memphis/102/72 
 
   
MOI 1 10334 19 0.18 
MOI 0.1 12003 106 0.88 
 
   
Mock Infected 
 
   
 
12532 12 0.10 
 
In Figure 32, cells infected with A/WSN/33 H1N1 multiplicity of infection (MOI) of 1  
showed a small amount of CD40+ cells. Groups of cells infected with the viral strains  
A/WSN/33 moi 0.1 and A/Memphis/102/72 moi 0.1 showed no marker expression of  
CD40 (Figures 33-36, Appendix A). Cells mock infected with 1X Trypsin also showed  
no expression of CD40. There was no expression found in the mock infected group of  
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cells. However, expression of CD40 was found with cells infected with MOI 1  
A/WSN/33.  
 
2.2.3  CD86 marker expression 
Cells infected with A/WSN/33 (MOI of 1 and 0.1), A/Memphis/102/72 (MOI of  
10, 1, 0.1) were stained with an antibody directed against the cellular marker CD86. A  
group of cells was also mock infected with diluted trypsin and then stained with the  
antibody. CD86 can be found on B cells, macrophages, and dendritic cells at low levels.  
It tends to be up-regulated on B cells when stimulated with the BCR complex, CD40, and  
some cytokine receptors. CD86 also plays a crucial role in T-B crosstalk, T cell  
co-stimulation, autoantibody production, and Th-2 mediated Ig production. The kinetics  
of up-regulation of CD86 upon stimulation supports its major contribution during the  
primary phase of an immune response. Table 8 shows the cells processed using flow  
cytometery and enumeration based on fluorescence.  
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Table 8. Cells stained with CD86 antibody. Two groups of cells were infected with 
A/WSN/33 MOI of 1 and 0.1. A second set of cells was infected with an 
A/Memphis/102/72 MOI of 1, and 0.1. The last group was mocked infected with 1X 
trypsin only. The second left column shows the total amount of cells enumerated by the 
flow cytometry machine. The middle column shows the number of cells expressing the 
CD86 marker. The far right column denotes the percentage of cells positive for 
expressing the CD86 marker.  
CD86 Total Cells Counted Marker + Cells % Marker + Cells 
    
A/WSN/33  
 
   
MOI 1 22633 6069 26.81 
MOI 0.1 10631 6210 58.41 
 
   
A/Memphis/102/72 
   
 
   
MOI 1 10751 4695 43.67 
MOI 0.1 10403 5033 48.38 
 
   
Mock Infected 
 
   
 
125507 3812 30.48 
 
 
Groups of cells infected with the viral strains A/WSN/33 and A/Memphis/102/72 showed  
CD86 marker expression (Figures 37-41 Appendix A). Cells mock infected with 1X 
trypsin also showed expression of CD86 (Figure 41, Appendix A). The cells infected 
with A/WSN/33MOI 1 showed a positive percentage of 26.81. In contrast, the cells 
infected with A/Memphis/102/72 MOI 1 showed a percentage of 43.67. The cells 
infected with the H3N2 strain expressed CD86 at higher levels. In comparison with both 
infections using a multiplicity of infection of 0.1, there is an increased expression in the 
marker with A/WSN/33. Cells infected with A/Memphis/102/72 demonstrated a lower 
level of expression. The mock infected cells expressed CD86 at a percentage of 30.48 
(Table 10). Therefore, there are differences in marker expression in each strain infection, 
as compared to the control group, and to each other. 
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2.2.4  MHC Class II marker expression 
Cells infected with A/WSN/33 (MOI of 1 and 0.1), A/Memphis/102/72 (MOI of 1, and  
0.1) were stained with an antibody directed against the cellular marker MHC Class II. A  
group of cells was also mock infected with diluted trypsin and then stained with the  
antibody. This marker is expressed on antigen presenting cells including B cells,  
monocytes, macrophages, dendritic cells, and activated T cells.  MHC Class II ultimately  
plays an important role in the presentation of pathogen peptides to CD4+ T lymphocytes.  
After infection, the cells were stained, and processed using flow cytometry. Table 9  
shows cell samples that were enumerated based on fluorescence.  
 
Table 9. Cells stained with MHC Class II antibody. Two groups of cells were infected 
with A/WSN/33 MOI of 1 and 0.1. A second set of cells was infected with an 
A/Memphis/102/72 MOI of 10, 1, and 0.1. The last group was mocked infected with 1X 
trypsin only. The second left column shows the total amount of cells enumerated by the 
flow cytometery machine. The middle column shows the number of cells expressing the 
MHC Class II marker. The far right column denotes the percentage of cells positive for 
expressing the MHC Class II marker. 
MHC Class II Total Cells Counted Marker + Cells % Marker + Cells 
    
A/WSN/33  
 
   
MOI 1 22846 6587 28.83 
MOI 0.1 11729 3197 27.26 
 
   
A/Memphis/102/72 
 
   
MOI 1 12342 895 7.25 
MOI 0.1 12156 895 7.36 
 
   
Mock Infected 
 
   
 
7571 540 7.13 
 
 
Differences between both infections are summarized in Figures 42- 46, Appendix A.  
A/WSN/33 infection MOI 1 showed a population of 28.83% MHC Class II positive cells.  
In contrast, A/Memphis/102/72 infection MOI 1 showed a population of 7.25% positive  
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cells. The same difference is noted in the infection using a MOI of 0.1, as seen in Table  
11. The cells infected with the H1N1 strain have a higher expression of the marker than  
do the H3N2 infected cells. The mock infected cells show an expression percentage of  
7.13. It can also be noted that the cells infected with A/Memphis/102/72 MOI 10 showed  
an expression of 5.9%.  
 
2.2.5 MHC Class I marker expression 
The cells infected with A/WSN/33 (MOI of 1 and 0.1), A/Memphis/102/72 (MOI of  
10, 1, 0.1) were stained with an antibody directed against the cellular marker MHC Class  
I. A group of cells was also mock infected with diluted Trypsin and then stained with the  
same marker. This antigen is expressed by all human nucleated cells, and these are key in  
cell-mediated immune response and tumor surveillance. After infection, the cells were  
stained, and processed using flow cytometry. As seen in Table 10, the cell samples were  
enumerated based on fluorescence.  
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Table 10. Cells stained with MHC Class I antibody. Two groups of cells were infected 
with A/WSN/33 MOI of 1 and 0.1 A second set of cells was infected with an 
A/Memphis/102/72 MOI of 1, and 0.1. The last group was mocked infected with 1X 
trypsin only. The second left column shows the total amount of cells enumerated by the 
flow cytometery machine. The middle column shows the number of cells expressing the 
MHC Class I marker. The far right column denotes the percentage of cells positive for 
expressing the MHC Class I marker.  
MHC Class I Total Cells Counted Marker + Cells % Marker + Cells 
    
A/WSN/33  
 
   
MOI 1 19613 15308 78.05 
MOI 0.1 8953 4758 53.14 
 
   
A/Memphis/102/72 
   
 
   
MOI 1 8881 5453 61.4 
MOI 0.1 6785 3104 45.75 
 
   
Mock Infected 
 
   
 
9537 5522 57.90 
 
As seen in Figures 47 through 51 in Appendix A, the group of cells infected with the viral  
strains A/WSN/33 and A/Memphis/102/72 showed differences in marker expression.  
A/WSN/33 infection MOI 1 showed a very high percentage of cells expressing MHC  
Class 1 antigen. In contrast, A/Memphis/102/72 showed a lower expression of 61.4%.  
With MOI of 0.1 for each virus, A/WSN/33 shows yet a higher percentage of expression  
than does A/Memphis/102/72 infection. As seen in Figure 51 in Appendix A, a sample  
was mock infected, and showed a 57.90% population of MHC Class I positive cells.  
From these results, it can be concluded that cells infected with the strains H3N2 and  
H1N1 showed differences in the incidence of expression for MHC Class I marker. 
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2.2.6 CD11b  marker expression 
The cells infected with A/WSN/33 (MOI of 1 and 0.1), A/Memphis/102/72 (MOI of  
10, 1, 0.1) were stained with an antibody directed against the cellular marker CD11b. A  
group of cells was also mock infected with diluted trypsin and then stained with the same  
marker. CD11b is an antigen that binds to a subset of molecules on neutrophils and  
monocytes after stimulation with chemokines. This then plays a role in adhesive cell  
interactions. After infection the cells were stained and processed using flow cytometry.  
Cell samples were enumerated by fluorescence using flow cytometry (Table 11). 
 
Table 11. Cells stained with CD11b antibody. Two groups of cells were infected with 
A/WSN/33 MOI of 1 and 0.1. A second set of cells was infected with A/Memphis/102/72 
MOI of 1, and 0.1. The last group was mocked infected with 1X trypsin only. The second 
left column shows the total amount of cells enumerated by the flow cytometry machine. 
The middle column shows the number of cells expressing the CD11b marker. The far 
right column denotes the percentage of cells positive for expressing the CD11b marker. 
CD11b Total Cells Counted Marker + Cells % Marker + Cells 
    
A/WSN/33  
 
   
MOI 1 6190 3 0.05 
MOI 0.1 6834 4 0.06 
 
   
A/Memphis/102/72 
 
   
MOI 1 6223 3 0.05 
MOI 0.1 6516 2 0.03 
 
   
Mock Infected 
 
   
 
8746 0 0.00 
 
The group of cells infected with the viral stains A/WSN/33 and A/Memphis/102/72  
showed no difference in CD11b marker expression (Figures 52-56, Appendix A). The  
mock-infected sample showed no expression of CD11b (Figure 56, Appendix A). From  
these results, it can be concluded that cells showed no difference in the level of CD11b  
expression.  
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2.2.7 BAFF marker expression 
Cells infected with A/WSN/33 (MOI of 1 and 0.1), A/Memphis/102/72 (MOI of  
1, and 0.1) were stained with an antibody directed against the cellular antigen BAFF. A  
group of cells was also mock infected with diluted trypsin and then stained with the same  
marker. BAFF is a type 11 membrane protein that exists in both membrane-bound and  
soluble forms. Expression of membrane-bound BAFF on monocytes is regulated by  
interferon gamma. The antigen acts as a potent B cell growth factor and co-stimulator of  
Ig production. After infection, the cells were stained, and processed using flow  
cytometry. Cell samples were enumerated by fluorescence using flow cytometry (Table  
12). 
 
Table 12. Cells stained with the BAFF antibody. Two groups of cells were infected with 
A/WSN/33 MOI of 1 and 0.1 A second set of cells was infected with an 
A/Memphis/102/72 MOI of 10, 1, and 0.1. The last group was mocked infected with 1X 
trypsin only. The second left column shows the total amount of cells enumerated by the 
flow cytometry machine. The middle column shows the number of cells expressing the 
BAFF marker. The far right column denotes the percentage of cells positive for 
expressing the BAFF marker.  
BAFF Total Cells Counted Marker + Cells % Marker + Cells 
    
A/WSN/33  
 
   
MOI 1 26803 6 0.02 
MOI 0.1 10548 4 0.04 
 
   
A/Memphis/102/72 
 
   
MOI 1 13068 2 0.02 
MOI 0.1 9955 6 0.06 
 
   
Mock Infected 
 
   
 
10314 3 0.03 
 
The group of cells infected with the viral strains A/WSN/33 and A/Memphis/102/72  
showed no difference in BAFF marker expression (Figures 57-61, Appendix A). The  
mock infected sample showed no expression of BAFF (Figure 61, Appendix A). From  
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these results, it can be concluded that cells showed no difference in the level of BAFF  
expression in any of the groups.  
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Discussion 
 
In this thesis work, dendritic cells were cultured from blood monocytes and infected with  
two strains of influenza and the expression of activation molecules on the cellular  
membranes were studied. A/WSN/33 is a strain of influenza virus belonging to the  
subtype group H1N1 that was isolated in 1933 and is a descendant of the virus  
responsible for the 1918 pandemic. A/Memphis/102/72 is another strain of influenza  
virus that belongs to the H3N2 subtype that was responsible for the 1967 pandemic. 
Although A/Memphis/102/72 (H3N2) continues to infect humans and is the cause of  
most acute cases of influenza infection today, while A/WSN/33 (H1N1) does not pose a  
risk for infection in humans. This is due to many passages in culture, and subsequently  
A/WSN/33 has lost its pathogenicity as a result. 
 
The immune response against cytopathic viruses in response to infection with  
A/Memphis/102/72 H3N2 was shown to decrease activation molecule expression on the  
cell membranes of dendritic cells, using A/WSN/33 H1N1 virus as a control. This  
hypothesis was tested by quantifying two strains of influenza virus and optimizing the  
technology to detect the presence of activation molecules on the membranes of cells.   
 
Embryonated chicken eggs were used to propagate both strains of influenza virus.  
A/Memphis/102/72 H3N2 grew well in the embryos and the titer for this stock was 5 x  
107 EID50% per mL and 512 by hemagglutination (Figures 9, and 11). A/WSN/33  
H1N1 grew less effectively in chicken embryos, and had a EID50% of 5 x 105 per mL  
and a hemagglutination titer of 256 (Figures 10, and 12), indicating the presence  
of  interferent particles in this viral stock. 
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After influenza virus propagation and quantification, peripheral blood mononuclear cells  
were characterized by membrane molecules using fluorescence microscopy. Cells were  
separated from whole blood and stained using biotinylated antibodies with specificity to  
certain molecules conjugated to fluorescent dyes. After the cells were incubated with the  
antibody, they were observed using an epifluorescent microscope, and the percentage of 
fluorescent cells was recorded (e.g., cells stained with an anti-CD4 antibody can be seen  
in Figure 14). To determine background staining, a biotinylated rat isotype control 
antibody conjugated to fluorescein was used.  As seen in Figure 13, no cells were 
identified as positive due to fluorescent staining. This validated the protocol used because 
no cells are expected to be positive with this antibody. 
 
After fluorescent cell staining was optimized the same protocol was then applied to  
characterize cells using flow cytometry. Cells were tagged with antibodies specific for  
membrane molecules, and processed. To determine background fluorescence using this  
technology, a biotinylated rat isotype control antibody conjugated to fluorescein was  
used.  This provided a negative control. In Figure 18, it is shown that no cells were 
identified as positive due to fluorescent staining using this antibody as expected for the 
negative isotype control used. As seen in Figure 19, cells stained with an antibody 
specific for cellular molecule CD19 were quantified using flow cytometry. CD19 is a 
molecule found mostly on B cells in humans. Positive cells in the sample demonstrated a 
high intensity of fluorescence due to the expression of this molecule. Eight and a half 
percent of positive cells were found using this antibody. This percentage is within the 
range of expected B cell frequency in peripheral mononuclear cells. 
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After this technology had been optimized, it was possible to proceed onto another crucial  
aspect of the project: production of dendritic cells by differentiation of monocytes.  
Dendritic cells are not as abundant in circulation as other immune system cells. Blood- 
derived monocytes differentiate into immature dendritic cells when cultured with  
cytokines IL-4 and GM-CSF. The percentage of monocytes in blood is 2-10% depending  
on the individual but it is possible to enrich this population using magnetic bead  
separation with antibodies against a molecule present on the monocytes cell membrane  
such as CD14. Therefore, it was necessary to optimize this technology for enrichment of  
monocytes from blood. As seen in Figure 23 before separation of monocytes, the 
occurrence of this population in blood was 6.07%. Optimization of the magnetic bead 
separation allowed the monocyte population to be enriched and was 26.24% (Figure 24).  
 
Once this protocol was optimized, high numbers of monocytes were stimulated using IL- 
4 and GM-CSF to develop into immature dendritic cells. It was possible to increase the  
dendritic cell population from 6.6% before cytokine treatment (Figure 25) to 34.85%  
after cytokine treatment (Figure 26).  
 
Monocyte-derived dendritic cells were then infected with influenza strains A/WSN/33  
H1N1 and A/Memphis/102/73 H3N2. Two different multiplicities of infection were used  
(MOI=1 and MOI=0.1), and dendritic cells were incubated for 4 hours after infection. An  
aliquot of cells were mock infected with 10% trypsin in RPMI, as a negative control. 
 The cells were then stained with a panel of antibodies specific for co-stimulation  
molecules expressed on dendritic cells. To determine background fluorescence within the  
experiment, a biotinylated rat isotype control antibody conjugated to fluorescein was  
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used. In Figure 18, no cells were identified as positive due to fluorescent staining using 
this antibody. This is expected, as this is an isotype control used.  
 
Antibodies specific for CD11b, and BAFF did not show a positive population of cells  
indicating that these two molecules were not expressed by the infected and mock-infected  
dendritic cells (Figures 52-61). CD11b is a typical marker for monocytes- 
macrophages and BAFF is a membrane molecule belonging to the family of Tumor  
Necrosis Factor that has been shown to be involved in activation of B cells by dendritic  
cells (17-19). Therefore, infection with these strains did not reverse the differentiation of  
dendritic cells to a monocyte-macrophage-like phenotype as it was described previously  
with foot-and-mouth disease virus (6). 
 
Proteins from virus infected cells are processed in the cytoplasm by proteasomes and  
expressed on the cell membrane in association with MHC Class I. Although these  
molecules are normally expressed on the cell membranes, infection increases expression.  
Therefore, expression of the MHC Class I molecule on dendritic cells can be used as an  
indication of virus replication. This molecule was expressed higher in cells infected with  
a MOI of 1 of A/WSN/33 H1N1 (78.05%) as compared to the mock infected dendritic  
cells (57.9%)  (Table 12).  However, cells infected with a MOI of 0.1 did not  
show an increase in expression (53.14%). The titer of A/WSN/33 H1N1 is 5 x 105  
EID50/ml but the titer by hemagglutination is high (256). This difference between a  
high HA and low EID strongly suggest the presence of interferent particles. Although the  
use of one infectious virus per cell clearly increases expression of MHC I, indicating the  
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presence of viral peptides due to viral infection, a lower MOI (0.1) does not increase 
MHC I, which is consistent with lack of viral replication.  
 
This result is congruent with the data showing high levels of interferent particles in this  
virus stock. Infection with A/Memphis/102/72 H3N2 that has a MOI of 1 or 0.1 does not  
induce expression of MHC I compared to the mock infected control. This is consistent  
with previous data in the literature indicating that the influenza virus induces an abortive  
infection (14,16);  blocking replication of the human strain of influenza may be due to  
the expression of α interferon by the dendritic cells.  
 
Interestingly, activation markers such as CD40, CD86 and MHC II (Tables 8, 10, and 11) 
increase expression in cells infected with A/WSN/33 H1N1 but not in cells infected with 
A/Memphis/107/72H3N2. Thus, dendritic cells seem to block replication of 
A/Memphis/107/72 but at the same time decrease the expression of activation molecules  
on the cell membrane. In contrast, A/WSN/33 H1N1 was able to replicate (as  
demonstrated by increase of MHC I expression on the cell membrane of the dendritic  
cells) and at the same time increased the  expression of activation markers.  
 
The results obtained with infection with the human influenza virus A/Memphis/107/72  
H3N2 are similar to the ones obtained with foot-and-mouth disease virus infecting mouse  
dendritic cells. The results obtained with the avian adapted A/WSN/33 H1N1 are similar  
to the those obtained with inactivated FMDV: either infection with this strain or uptake   
of inactivated FMDV increases expression of activation markers (6).  
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Two explanations could account for this behavior by A/WSN/33 H1N1: 1) the high  
proportion of interferent particles that encourage  this virus to act  as an inactivated virus,  
or 2) though there is replication of the virus, the level of replication is not enough to alert  
“danger-signal” receptors in the cytoplasm of the dendritic cells. Nonetheless, this strain  
is sensed by the dendritic cell as a particular non-infectious antigen. Subsequently  
dendritic cells drive the response into a classical T-cell dependent pathway.  
 
In the case of strain A/Memphis/107/72H3N2, dendritic cells block replication (abortive  
replication) but the level of infection is still enough to activate the danger signal  
molecules in the cytoplasm of the infected dendritic cell. This drives the dendritic cell to  
a pathway in which no T cells will be activated (T cell independent) as it is the case for  
influenza (4). This pathway is similar to the one described in FMDV-infected dendritic  
cells (6) and allows for the suggestion that a similar mechanism is in place for both  
viruses: infection with a pathogenic influenza virus strain is sensed by the human  
dendritic cell which is alerted by danger receptors.  
 
As a result, virus replication is aborted, possibly by α-interferon. This mechanism leads  
to a decrease of activation markers which will not activate T cells, thus decreasing  
inflammation. In conclusion, infected dendritic cells directly activate B cells to produce  
antibodies by a different mechanism other than BAFF-APRIL engagement. The overall  
results of the cross-talk are a decrease in inflammation at the beginning of the infection  
with a rapid induction of neutralizing antibodies (17-19). 
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APPENDIX A 
 
Figures 21 through 61 
 
 
  
Figure 27. Flow cytometry analysis for cells infected with A/WSN/33 MOI 0.1, and then 
stained with rat isotype control antibody. The left scatter plot diagram shows the output 
of cells stained with fluorescence. The diagram on the right indicates the output for the 
number of cells versus intensity of fluorescence. 
 
 
 
  
Figure 28. Flow cytometry analysis for cells infected with A/WSN/33 MOI 1, and then 
stained with rat isotype control antibody. The left scatter plot diagram shows the output 
of cells stained with fluorescence. The diagram on the right indicates the output for the 
number of cells versus intensity of fluorescence. 
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Figure 29. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 0.1, 
and then stained with rat isotype control antibody. The left scatter plot diagram shows the 
output of cells stained with fluorescence. The diagram on the right indicates the output 
for the number of cells versus intensity of fluorescence. 
 
 
 
 
 
 
 
  
Figure 30. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 1, 
and then stained with rat isotype control antibody. The left scatter plot diagram shows the 
output of cells stained with fluorescence. The diagram on the right indicates the output 
for the number of cells versus intensity of fluorescence. 
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Figure 31. Flow cytometry analysis for cells mock infected with 1X trypsin, and then 
stained with rat isotype control antibody. The left scatter plot diagram shows the output 
of cells stained with fluorescence. The diagram on the right indicates the output for the 
number of cells versus intensity of fluorescence. 
 
 
 
 
 
 
 
 
Figure 32. Flow cytometry analysis for cells infected with A/WSN/33 MOI 1, and then 
stained with CD40. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
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Figure 33. Flow cytometry analysis for cells infected with A/WSN/33 MOI 0.1, and then 
stained with CD40. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
 
 
 
 
 
Figure 34. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 1, 
and then stained with CD40. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
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Figure 35. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 1, 
and then stained with CD40. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
 
 
 
 
 
 
Figure 36. Flow cytometry analysis for cells mock infected with 1X trypsin, and then 
stained with CD40. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
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Figure 37. Flow cytometry analysis for cells infected with A/WSN/33 MOI 1, and then 
stained with CD86. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
 
 
 
 
 
 
 
 
 
Figure 38. Flow cytometry analysis for cells infected with A/WSN/33 MOI 0.1, and then 
stained with CD86. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
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Figure 39. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 1, 
and then stained with CD86. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
 
 
 
 
 
 
  
Figure 40. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 0.1, 
and then stained with CD86. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
 
73 
 
  
Figure 41. Flow cytometry analysis for cells mock infected with 1X trypsin, and then 
stained with CD86. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
 
 
 
 
 
 
 
 
  
Figure 42. Flow cytometry analysis for cells infected with A/WSN/33 MOI 1, and then 
stained with MHC Class II. The left scatter plot diagram shows the output of cells stained 
with fluorescence. The diagram on the right indicates the output for the number of cells 
versus intensity of fluorescence. 
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Figure 43. Flow cytometry analysis for cells infected with A/WSN/33 MOI 0.1, and then 
stained with MHC Class II. The left scatter plot diagram shows the output of cells stained 
with fluorescence. The diagram on the right indicates the output for the number of cells 
versus intensity of fluorescence. 
 
 
 
 
 
 
 
 
  
Figure 44. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 1, 
and then stained with MHC Class II. The left scatter plot diagram shows the output of 
cells stained with fluorescence. The diagram on the right indicates the output for the 
number of cells versus intensity of fluorescence. 
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Figure 45. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 0.1, 
and then stained with MHC Class II. The left scatter plot diagram shows the output of 
cells stained with fluorescence. The diagram on the right indicates the output for the 
number of cells versus intensity of fluorescence. 
 
 
 
 
 
 
 
 
  
Figure 46. Flow cytometry analysis for cells mock infected with 1X trypsin, and then 
stained with MHC Class II. The left scatter plot diagram shows the output of cells stained 
with fluorescence. The diagram on the right indicates the output for the number of cells 
versus intensity of fluorescence 
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Figure 47. Flow cytometry analysis for cells infected with A/WSN/33 MOI 1, and then 
stained with MHC Class I. The left scatter plot diagram shows the output of cells stained 
with fluorescence. The diagram on the right indicates the output for the number of cells 
versus intensity of fluorescence. 
 
 
 
 
 
 
 
 
  
Figure 48. Flow cytometry analysis for cells infected with A/WSN/33 MOI 0.1, and then 
stained with MHC Class I. The left scatter plot diagram shows the output of cells stained 
with fluorescence. The diagram on the right indicates the output for the number of cells 
versus intensity of fluorescence. 
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Figure 49. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 1, 
and then stained with MHC Class I. The left scatter plot diagram shows the output of 
cells stained with fluorescence. The diagram on the right indicates the output for the 
number of cells versus intensity of fluorescence. 
 
 
 
 
 
 
 
  
 
Figure 50. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 0.1, 
and then stained with MHC Class I. The left scatter plot diagram shows the output of 
cells stained with fluorescence. The diagram on the right indicates the output for the 
number of cells versus intensity of fluorescence. 
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Figure 51. Flow cytometry analysis for cells mock infected with 1X trypsin, and then 
stained with MHC Class I. The left scatter plot diagram shows the output of cells stained 
with fluorescence. The diagram on the right indicates the output for the number of cells 
versus intensity of fluorescence. 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. Flow cytometry analysis for cells infected with A/WSN/33 MOI 1, and then 
stained with CD11b. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
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Figure 53. Flow cytometry analysis for cells infected with A/WSN/33 MOI 0.1, and then 
stained with CD11b. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
 
 
 
 
 
 
 
 
  
Figure 54. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 1, 
and then stained with CD11b. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
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Figure 55. Flow cytometry analysis for cells infected with A/Memphis/102/72 MOI 0.1, 
and then stained with CD11b. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
 
 
 
 
 
 
 
  
Figure 56. Flow cytometry analysis for cells mock infected with 1X trypsin, and then 
stained with CD11b. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
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Figure 57. Flow cytometry analysis for cells infected A/WSN/33 MOI 1, and then stained 
with BAFF antibody. The left scatter plot diagram shows the output of cells stained with 
fluorescence. The diagram on the right indicates the output for the number of cells versus 
intensity of fluorescence. 
 
 
 
 
 
 
 
 
  
Figure 58. Flow cytometry analysis for cells infected A/WSN/33 MOI 0.1, and then 
stained with BAFF antibody. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
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Figure 59. Flow cytometry analysis for cells infected A/Memphis/102/72 MOI 1, and 
then stained with BAFF antibody. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
 
 
 
 
 
 
 
 
  
Figure 60. Flow cytometry analysis for cells infected A/Memphis/102/72 MOI 0.1, and 
then stained with BAFF antibody. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
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Figure 61. Flow cytometry analysis for cells mock infected with 1X trypsin, and then 
stained with BAFF antibody. The left scatter plot diagram shows the output of cells 
stained with fluorescence. The diagram on the right indicates the output for the number of 
cells versus intensity of fluorescence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
APPENDIX B 
 
 
Preparation of solutions used in this work 
 
 
1. Alsevers solution  
20.5 grams Dextrose 
7.9 grams Sodium Citrate · 2H2O (27 mM) 
4.2 grams NaCl (71 mM) 
Dissolve reagents in 50 mL distilled water. Adjust pH with 1M Citric Acid Solution. 
Filter sterilize. Store at -20°C. 
 
 
2.) 1 M Citric Acid Solution 
Dissolve 48.0325 grams in 250 mL distilled water. Store at room temperature. 
 
 
3.) 5% FCS-RPMI 
5 mL sterile fetal calf serum 
95 mL sterile RMPI (Invitrogen) 
Add 95 mL RMPI to 5 mL FCS in autoclaved glass bottle in sterility. Store at 4°C 
 
 
4.) 10X PBS pH 7.4 
2.62 grams NaH2PO4 
11.5 grams Na2HPO4 
43.84 grams NaCl 
Combine all ingredients in 250 mL distilled water. Adjust pH to 7.4 Add 250 mL distilled 
water. Autoclave 
 
 
5.) 1X PBS pH 7.4 
100 mL 10X PBS pH 7.4 
900 mL distilled water 
Combine 100 mL 10X PBS and 900 mL distilled water in glass bottle. Autoclave. Store 
at room temperature. 
 
 
5.) 2% BSA solution 
10 mL of 10X PBS 
90 mL distilled water 
2 grams BSA 
Add 90 mL distilled water to 10 mL 10X PBS. Add 2 grams BSA. Stir to mix. Filter 
sterilize. Aliquot in 10 mL amounts. Store at -20°C. 
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6.) 1% Paraformaldehyde solution 
0.1 grams paraformaldehyde 
100 mL 1X PBS 
Add 0.1 grams paraformaldehyde to 50 mL 1X PBS. Raise pH to 10. Heat to dissolve. 
Add additional 50 mL 1X PBS. Lower pH to 7. Store at room temperature.  
 
 
7.) Separation buffer 
0.2 mL 5 M EDTA Solution (Gibco) 
1X PBS 
Biotin free BSA 
Add 0.2 mL EDTA solution to 499.6 mL 1X PBS. Add 2.5 grams BSA to solution. Filter 
sterilze. Aliquot into 5 and 10 mL amounts. Store at -20°C. 
 
 
8.) Human Dendritic Cell Culture Medium 
89.5 mL sterile RPMI 
10 mL FCS 
12 microliters Recombinant Human GM-CSF (eBioscience) 
12 microliters Recombinant Human IL-4 (eBioscience) 
400 microliters Penicillin-Streptomycin (Gibco) 
Add 89.5 mL RMPI to sterile glass bottle. Add antibiotics, and cytokines. Add 10 mL 
FCS and pipette to mix. Store at 4°C.  
 
 
9.) 1X Trypsin 
10 mL Trypsin 
90 mL sterile RPMI 
Add 90 mL RPMI to 10 mL trypsin in sterile bottle. Store at 4°C. 
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APPENDIX C 
 
 
Approval for Vertebrate Use 
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APPENDIX D 
 
 
Approval for use of human subjects 
 
 
 
 
 
 
 
